Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Primus Corporation dba Trinity Biotech
WARNING LETTER
•Primus Corporation dba Trinity Biotech•February 6, 2020

Primus Corporation dba Trinity Biotech – FDA Warning Letter, Feb 6, 2020

Record Details

The FDA issued a Warning Letter to Primus Corporation dba Trinity Biotech following an inspection from January 27 to February 6, 2020, at their Kansas City, MO facility. The inspection revealed that their ultra2 Resolution Variants System, a device intended for disease diagnosis, is adulterated and misbranded.

The device is adulterated because the firm lacks an approved premarket approval (PMA) application or an investigational device exemption. It is misbranded because the firm failed to notify the FDA of its intent to introduce the device into commercial distribution via a 510(k) premarket notification. Evidence from 2018 and 2020 inspections indicates the ultra2 Resolution Variants System is a new device, created by significant changes to the previously cleared PVS99 (K955283), including modifications to the analytical column and sample analysis time, which significantly affect safety or effectiveness. Additionally, the ultra2 system claims to detect hemoglobin variants (HbS, HbC, HbE, HbD-Los Angeles) not supported by the PVS99's original 510(k) data, raising public health concerns regarding accuracy and potential for misdiagnosis. The firm continues to distribute modified columns and falsely advertises the ultra2 as "FDA cleared."

The devices are also adulterated under 21 CFR Part 820 for non-conformity with Quality System regulation. Specific violations

Company
Primus Corporation dba Trinity Biotech
Inspection date
February 6, 2020
Product type
Devices
Office
Center for Devices and Radiological Health
People
  • Blake Bevill (Director)
  • Donald St. Pierre
  • Timothy T. Stenzel (Director)
View Company Profile

ID · 20468464-6d2d-4c66-a80d-b02394382ec7

Violation Codes10
21 U.S.C. 321(h)21 U.S.C. 351(f)(1)(B)21 U.S.C. 360e(a)21 U.S.C. 360j(g)21 U.S.C. 352(o)21 U.S.C. 360(k)21 CFR 807.81(b)21 CFR 807.81(a)(3)(i)21 CFR 82021 U.S.C. 351(h)

Full citation text and observation details available on the Dashboard.

Other documents for Primus Corporation dba Trinity Biotech
  • 483 - 2020-02-06February 6, 2020

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Primus Corporation dba Trinity Biotech
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.